Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine

• DOI: 10.1097/qai.0b013e31802bf122
• Publication Date: 2006-11-22T18:59:54Z
• Authors: Daniel Podzamczer; Elena Ferrer; Pochita Sanchez; José M Gatell; Manel Crespo; Cesar Fisac; Montse Lonca; Jose Sanz; Jordi Niubo; Sergio Veloso; Josep M Llibre; Pilar Barrufet; María A Ribas; Esperanza Merino; Esteban Ribera; Javier Martínez-L...; Carlos Alonso; Miquel Aranda; Federico Pulido; Juan Berenguer; Antonio Delegido; Juan D Pedreira; Ana Lérida; Rafael Rubio; Luis del Río
• Keywords: Stavudine; Lipoatrophy; Abacavir; Lipodystrophy; Efavirenz; Lipid Profile

To assess lipoatrophy, other toxicities, and efficacy associated with abacavir as compared stavudine in HIV-infected antiretroviral-naive patients.This was a prospective, randomized, open trial, stratified by viral load CD4 cell count, conducted January 2001 to July 2004. Two hundred thirty-seven adult patients HIV infection initiating antiretroviral therapy were assigned receive (n = 115) or 122), both combined lamivudine efavirenz. The primary endpoint the proportion of lipoatrophy assessed physician patient observation at 96 weeks.A lower developed clinical signs (4.8% vs. 38.3%; P < 0.001). These observations confirmed anthropometric data. Dual energy x-ray absorptiometry (DEXA) scans performed 57 showed significantly greater total limb fat loss arm (-1579 913 g; lipid profile presented more favorable changes levels triglycerides (P 0.03), high-density lipoprotein cholesterol (HDLc; 0.001), apolipoprotein A1 0.001) well ratio between HDLc 0.005). Throughout study, higher group received lipid-lowering agents (17% 4%; 0.002). Similar virologic immunologic responses observed.Assuming limitations inherent assessment, this study shows notably weaker association than stavudine. DEXA measurements supported findings. In addition, that occurred receiving abacavir.